Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Pernix issues $25mm in stock to buy Silenor marketer Somaxon Pharmaceuticals

Executive Summary

Pernix Therapeutics Holdings Inc. (brand, generic, and OTC products) is issuing $25mm of its common stock--about 3.4mm shares based on the ten-day average--to acquire publicly traded spec pharmaco Somaxon Pharmaceuticals Inc., which has been evaluating strategic alternatives since December 2011.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Stock

Related Companies